Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1001/jama.1952.02930230024007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ethical dilemmas surrounding patients´ "unwise" treatment preferences and suboptimal decision quality: case series of three renal cell carcinoma patients who developed local recurrences after non-guideline-concordant care choices.
Pan Afr Med J
October 2024
College of Medicine, Qatar University, Doha, Qatar.
Patient engagement and shared decision-making (SDM) between patients and clinicians is the foundation of patient-centered care. It aims to reach a treatment option that fits the patient's preference and is guideline-concordant. We sought to evaluate the possible causes and outcomes of patient's non-guideline-concordant care choices.
View Article and Find Full Text PDFThe PIKASO trial (Preventing Injured Knees from Osteoarthritis: Severity Outcomes): Rationale and design features for a randomized controlled trial.
Osteoarthr Cartil Open
March 2025
Brigham and Women's Hospital, Boston, MA, USA.
Objective: Given the high burden and increasing prevalence of post-traumatic osteoarthritis (PTOA), identifying clinically beneficial strategies to prevent or delay its onset could improve the quality of life of those at high risk of developing the disease.
Methods: Preventing Injured Knees from OsteoArthritis: Severity Outcomes (PIKASO) is a multicenter blinded, parallel, two-arm randomized controlled trial of 512 individuals aged 18-45 years undergoing anterior cruciate ligament reconstruction (ACLR). This study is designed to evaluate the efficacy of a 12-month intervention of oral metformin vs.
Artificial intelligence assisted virtual reality training module for Gasserian ganglion block.
Interv Pain Med
March 2025
Department of Anesthesiology, Perioperative, and Pain Medicine, Weill Cornell Medicine, New York, NY, USA.
•: The AI-assisted VR module enables learners to engage in a 360-degree immersive environment, manipulating holographic anatomy models and simulating fluoroscopic guidance to perform the Gasserian ganglion block.•: Key anatomical landmarks, like the foramen ovale, are highlighted, and proper C-arm positioning is demonstrated, helping practitioners localize the target area for needle advancement.•: The module includes AI-driven multi-language options and AI-generated multiple-choice questions to enhance learning and retention.
View Article and Find Full Text PDFYale-Brown Obsessive-Compulsive Scale Modified for Body Dysmorphic Disorder: Factor Structure and Construct Validity of Subfactors.
J Obsessive Compuls Relat Disord
July 2024
Department of Psychiatry, Massachusetts General Hospital/Harvard Medical School.
The Yale-Brown Obsessive-Compulsive Scale modified for Body Dysmorphic Disorder (BDD-YBOCS) is a semi-structured interview designed to assess the severity of current BDD. The aim of the study was to examine the factor structure and construct validity of the BDD-YBOCS. The sample included 366 adults with BDD who completed the BDD-YBOCS and other measures of BDD severity/impairment, psychiatric distress (i.
View Article and Find Full Text PDFEfficacy, Safety, Pharmacokinetics, and Immunogenicity of ABBV-154 in Adults With Glucocorticoid-Dependent Polymyalgia Rheumatica: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial.
Arthritis Rheumatol
January 2025
Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Rheumatology and Clinical Immunology, 10117, Berlin, Germany.
Objective: An unmet need exists for glucocorticoid-sparing treatments for patients with polymyalgia rheumatica (PMR). The antibody-drug conjugate ABBV-154 comprises adalimumab conjugated to a glucocorticoid receptor modulator. We evaluated ABBV-154 versus placebo in patients with glucocorticoid-dependent PMR.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!